Q1 Earnings Forecast for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($1.35) for the quarter, down from their prior estimate of ($1.31). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.77) EPS, FY2028 earnings at $8.60 EPS and FY2029 earnings at $15.05 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

A number of other research firms have also recently commented on AXSM. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target for the company. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, April 3rd. Finally, Morgan Stanley upped their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $169.80.

Axsome Therapeutics Stock Performance

AXSM stock opened at $104.46 on Wednesday. The firm has a market cap of $5.09 billion, a PE ratio of -17.44 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a 50-day moving average price of $118.71 and a 200-day moving average price of $102.30. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $139.13.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. NBC Securities Inc. bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $31,000. Raiffeisen Bank International AG bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $51,000. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics in the fourth quarter worth $52,000. R Squared Ltd bought a new position in shares of Axsome Therapeutics during the fourth quarter worth $64,000. Finally, Aquatic Capital Management LLC purchased a new position in Axsome Therapeutics during the fourth quarter valued at $76,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.